Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
Want to see AU:RHY full AI Analyst Report?
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$51.88M
Enterprise ValueAU$46.39M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding364,059,840
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA high gross margin indicates attractive unit economics for Rhythm's blood-based colorectal screening test. Once testing volumes scale through healthcare partners, strong gross margins can sustain profitability, fund R&D and marketing, and provide pricing flexibility versus competitors.
Improving Free Cash Flow TrendAn improving free cash flow trend and a FCF-to-net-income ratio slightly above 1 (even while negative) signal better cash conversion dynamics. Sustained improvement reduces ongoing financing needs and supports funding of commercial rollout as per-test revenues begin to ramp.
Focused Screening Product & Clear Commercial PathwayA focused business model targeting colorectal cancer screening addresses a large, structural screening market with recurring per-test revenue potential. A clear commercialisation pathway through healthcare systems and partnerships supports durable revenue once regulatory and reimbursement milestones are achieved.
Bears Say
Sharp Revenue DeclineA 42.87% year-over-year revenue drop signals material weakness in commercial traction or timing of market adoption. Persistent top-line contraction undermines scale economics, delays margin improvement, and lengthens the timeframe to achieve self-sustaining operations.
Persistent Negative Operating MarginsConsistently negative net, EBIT and EBITDA margins indicate the company has not attained operating leverage. Even with favorable gross margins, an adverse cost structure or low volumes keeps overall profitability negative, requiring substantial revenue growth to reach break-even.
Elevated Leverage & Negative Operating Cash FlowA debt-to-equity ratio of 1.68 combined with negative operating cash flow raises refinancing and liquidity risk. Elevated leverage constrains strategic flexibility, increases financing costs, and may force dilutive capital raises that impede long-term commercial expansion.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$51.88M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 99 days.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-476.27%
Trailing 12-Months
Asset Growth
-47.76%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---